These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 33578192

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ, Kim H, Shin K, Hong TH, Suh JH, Lee MA.
    BMC Cancer; 2021 Nov 03; 21(1):1176. PubMed ID: 34732161
    [Abstract] [Full Text] [Related]

  • 4. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
    Tezuka S, Ueno M, Kobayashi S, Hamaguchi T, Yamachika Y, Oishi R, Nagashima S, Fukushima T, Morimoto M, Shin M.
    Pancreatology; 2022 Sep 03; 22(6):789-796. PubMed ID: 35705458
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
    Tang CY, Yang SH, Li CP, Su YY, Chiu SC, Bai LY, Shan YS, Chen LT, Chuang SC, Chan DC, Yen CJ, Peng CM, Chiu TJ, Chen YY, Chen JS, Chiang NJ, Chou WC.
    Pancreatology; 2024 Jun 03; 24(4):600-607. PubMed ID: 38565467
    [Abstract] [Full Text] [Related]

  • 9. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
    Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D.
    Pancreas; 2020 Feb 03; 49(2):193-200. PubMed ID: 32011529
    [Abstract] [Full Text] [Related]

  • 10. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J.
    Clin Res Hepatol Gastroenterol; 2020 Jun 03; 44(3):295-301. PubMed ID: 31607641
    [Abstract] [Full Text] [Related]

  • 11. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T, Sasaki T, Okamoto T, Takeda T, Mori C, Furukawa T, Kasuga A, Matsuyama M, Ozaka M, Sasahira N.
    Jpn J Clin Oncol; 2022 Dec 05; 52(12):1399-1407. PubMed ID: 36111430
    [Abstract] [Full Text] [Related]

  • 12. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G, Cockrum P, Surinach A, Wang S, Wainberg Z.
    Curr Med Res Opin; 2022 Aug 05; 38(8):1295-1303. PubMed ID: 35354375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
    Nagashima S, Kobayashi S, Tsunoda S, Yamachika Y, Tozuka Y, Fukushima T, Morimoto M, Ueno M, Furuse J, Maeda S.
    Int J Clin Oncol; 2024 Feb 05; 29(2):188-194. PubMed ID: 37991558
    [Abstract] [Full Text] [Related]

  • 15. Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.
    Hyung J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, Cheon J, Kang BW, Ryu H, Lee JS, Kim KW, Abou-Alfa GK, Yoo C.
    JAMA Oncol; 2023 May 01; 9(5):692-699. PubMed ID: 36951834
    [Abstract] [Full Text] [Related]

  • 16. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
    Procaccio L, Merz V, Fasano M, Vaccaro V, Giommoni E, Pretta A, Noventa S, Satolli MA, Giordano G, Zichi C, Pinto C, Zecchetto C, Barsotti G, De Vita F, Milella M, Antonuzzo L, Scartozzi M, Zaniboni A, Spadi R, Casalino S, Bergamo F, De Toni C, Melisi D, Lonardi S.
    Cancer Med; 2023 Jul 01; 12(13):14337-14345. PubMed ID: 37278395
    [Abstract] [Full Text] [Related]

  • 17. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
    Lee JC, Woo SM, Shin DW, Kim J, Yang SY, Kim MJ, Kim JW, Kim JW, Lee WJ, Cha HS, Park P, Kim J, Hwang JH.
    Am J Clin Oncol; 2020 Sep 01; 43(9):654-659. PubMed ID: 32889836
    [Abstract] [Full Text] [Related]

  • 18. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA.
    Eur J Cancer; 2018 Dec 01; 105():71-78. PubMed ID: 30414528
    [Abstract] [Full Text] [Related]

  • 19. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ, Chang JY, Shan YS, Chen LT.
    Expert Opin Pharmacother; 2016 Jul 01; 17(10):1413-20. PubMed ID: 27140876
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.